With the company's analyst day behind it, Neurocrine Biosciences (NASDAQ:NBIX)
is looking well. This biotech could have two approved drugs in hand
within a couple of years that each generate more than $1 billion in
sales (at peak), plus a third drug with solid potential as an orphan
indication. Better still, I don't believe it takes particularly robust
expectations to generate an attractive fair value for the stock and
significant trial data read-outs this year could unlock significant
value if the data are positive.
Click here for the full article:
All Is Well With Neurocrine Biosciences, And It Could Get Better
No comments:
Post a Comment